We are happy to see the announcement of the Danish trial "Fibromyalgia and Naltrexone The FINAL Study" which will look at Low Dose Naltrexone and how it may help fibromyalgia. It is still early but this study follows previous pilot studies by Jarred Younger on LDN when he was at Stanford. We still do not know if there is a good base for LDN being used in fibro although we do have anecdotal evidence as well some pilot results but studies like this need to be done.
"This study evaluates the effect of low dose naltrexone (LDN) on pain in women with fibromyalgia (FM). The study is designed as a parallel randomised (1:1) double blind, placebo-controlled superiority trial. Half of the participants will receive treatment with LDN while the other half will receive treatment with placebo."
While it is recruiting at present and will take a while before any results are presented, we do find it of interest that they are using a pill formulation. We are aware that people that do use it within the UK are required to jump through a number of hoops to get it in liquid form using specialist pharmacies.
While caution is always required with clinical studies as they take years and can be fruitless. We can have a flurry of news articles including main stream media based on initial study results and lots of hope raised for people with fibromyalgia. But it can be 6 months later without any fanfare that the study can be retracted or not able to be replicated. We have seen this with recent diabetes articles and the study they were based on being retracted.
So while this is hopeful and shows research happening around the world and that research has no country as ideas feed off of others, there is hope to found. It may not be as quick as we want but work is being done by researchers to help those with fibromyalgia as well as those with chronic pain.
bioportfolio.com/resources/...
Previous pilot study article: "Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomised, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels." ncbi.nlm.nih.gov/pubmed/233...